Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The Vivistim System includes an implantable device that stimulates the vagus nerve only when intentionally activated, triggering the release of neuromodulators, including acetylcholine, norepinephrine, and serotonin. Its neuromodulators create a heightened state of plasticity in the brain, such that neural networks can more readily adapt and reform in response to stimuli. The implantable components of the Vivistim System-namely, the implantable pulse generator (IPG) and lead-are implanted through a minimally invasive outpatient procedure that takes approximately 60 minutes.
BörsenkürzelMOBI
Name des UnternehmensMobia Medical Inc
IPO-datumMay 08, 2026
CEOFoust (Richard John)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse2802 Flintrock Trace, Suite 226
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl78738
Telefon
Website
BörsenkürzelMOBI
IPO-datumMay 08, 2026
CEOFoust (Richard John)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten